Communiqués PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
78,59 ^USD	+0,09%		-7,38%	+3,46%

07/07	PTC THERAPEUTICS, INC. : RBC Capital Markets maintient sa recommandation neutre	ZM
16/06	PTC Therapeutics fixe les conditions d'une émission obligataire de 500 millions de dollars	MT

Communiqués

17/06	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
16/06	PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
15/06	PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes	PR
10/05	PTC Therapeutics : Corporate Presentation – May 2026	PU
08/05	PTC Therapeutics : Q1 2026 FLS	PU
08/05	PTC Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	PTC Therapeutics: Q1 Earnings Snapshot	AQ
07/05	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results	PR
04/05	PTC Therapeutics to Participate in Upcoming Investor Conferences	PR
28/04	PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026	PU
28/04	PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam	PR
28/04	PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study	PR
22/04	PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026	PR
17/04	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
25/03	PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors	PR
13/03	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
23/02	PTC Therapeutics to Participate at Upcoming Investor Conferences	PR
19/02	PTC Therapeutics: Q4 Earnings Snapshot	AQ
19/02	PTC Therapeutics : Corporate Presentation – February 2026	PU
19/02	PTC Therapeutics : Q4 2025 FLS	PU
19/02	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results	PR
12/02	PTC Therapeutics Provides Regulatory Update on Translarna™	PR
05/02	PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026	PR
22/01	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/01	PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference	PR